Verastem (VSTM) Stock Analysis & AI Equity Report
Verastem (VSTM) overview
Verastem (VSTM) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 30.9m and operating profit of USD -170m; the year-end share price was 7.72 USD and market capitalisation was USD 600m. Verastem is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Verastem's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Verastem
Verastem is a biopharmaceutical company that develops and commercializes medicines for cancers driven by RAS/MAPK pathways. It markets AVMAPKI FAKZYNJA CO-PACK in the United States for adults with KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic therapy. Its pipeline includes clinical-stage and preclinical drug programs, including treatments under evaluation for other cancers.
Generate the Verastem report
Verastem is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Verastem and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Verastem
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.